Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-Year data from SELECT-COMPARE
Rheumatol Ther 2024 doi: 10.1007/s40744-024-00658-1 Epub ahead of print
Fleischmann, et al. found that patients who switched from adalimumab to upadacitinib and vice versa following lack of improvement showed improvements in disease activity measures and functional outcomes through 228 weeks.
Patients from the SELECT-COMPARE trial that switched treatments in the first 26 weeks of the trial were included in the study. Patients who did not achieve ≥20% improvement from baseline in TJC68 and SJC66 were switched at Weeks 14, 18, or 22. Patients who did not achieve CDAI ≤10 were switched at Week 26.
Keywords:
